Home  |  Important Safety Information  |  Full Prescribing Information PDF  |  Contact Us  |  Site Map
Register for More Information  |  Send to a Friend
A
A
A
Print
Migraines afflict approximately 21 million women in the United States – about 3 times more women than men.8

Learn more about migraines
Learn About Migraines

Do you have migraines that are long in duration and/or recur? Can you recognize the signs of a migraine attack?

Learn about migraines

View profiles of people with migraine
Talk To Your Doctor

A study demonstrated that early migraine treatment is more likely to provide pain relief.18 Track your migraines and talk to your doctor.

What questions should you ask your doctor?

Track your migraines
Learn About FROVA®

FROVA is FDA-approved for the acute treatment of migraine attacks with or without aura in adults.19

About FROVA

Is FROVA Right For Me?
The most common side effects associated with the use of FROVA are dizziness, tiredness, feeling of tingling, hot flashes, headache (other than migraine headache), dry mouth, hot or cold sensation, pain in joints or bones, chest pain, and indigestion.
+ View references
  1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia. 2004;24(suppl 1):24-36; 138-149. Available at: http://216.25.100.131/ihscommon/guidelines/pdfs/ihc_II_main_no_print.pdf. Accessed January 19, 2007.
  2. American Council for Headache Education. Headache diary. Available at: http://www.achenet.org/resources/diary.php. Accessed February 21, 2007.
  3. National Headache Foundation. Serotonin. Available at: http://www.headaches.org/consumer/topicsheets/serotonin.html. Accessed February 21, 2007.
  4. American Council for Headache Education. Women and headaches. Available at: http://www.achenet.org/news/women.php. Accessed February 21, 2007.
  5. American Council for Headache Education. Migraine and coexisting conditions. Available at: http://www.achenet.org/news/macc.php. Accessed February 21, 2007.
  6. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: the Depo-Estradiol challenge test. Headache. 1996;36:367-371.
  7. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3:354-361.
  8. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
  9. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33:385-389.
  10. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2002;42:185-193.
  11. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24:707-716.
  12. Couturier EGM, Bomhof MAM, Knuistingh Neven A, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23:302-308.
  13. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351-353.
  14. Martin VT, Wernke S, Mandell K, et al. Defining the relationship between ovarian hormones and migraine headache. Headache. 2005;45:1190-1201.
  15. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(72):2154-2158. doi: 10.1212/01.wnl.0000233888.18228.19.
  16. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.
  17. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55:754-762.
  18. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Res Med Opin. 2004; 20(9):1465-1472. doi: 10.1185/030079904x2745.
  19. FROVA® [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2007.
  20. Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006;46(6):942-953. doi:10.1111/j.1526-4610.2006.00443.x.
  21. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773-780. doi:10.1111/j.1526-4610.2006.00437.x.
  22. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1-12.
  23. FROVA® Patient Product Information. Chadds Ford, PA: Endo Pharmaceuticals; 2007.
     

    Important Safety Information

    For more information, please see Full Prescribing Information for FROVA at http://www.frova.com/pi.